Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
RLF-TD011 investigator-initiated trial results for EB wound treatment anticipated in the coming weeks
RLF-OD032 pilot PK study progresses with potential NDA filing by mid- to late 2025
Streamlined operations and CHF 15.1 million cash reserves expected to provide funding into at least 2026
預計RLF-TD011獨立研究試驗的Eb創傷治療結果將在未來幾周內公佈。
RLF-OD032試點Pk研究取得進展，預計2025年中至晚前提交新藥申請。
經過精簡的營運和1510萬元現金儲備，預計能夠提供資金支持至少到2026年。
GENEVA, SWITZERLAND / ACCESSWIRE / August 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today reported its financial results for the half-year ended June 30, 2024, and provided a corporate update.
瑞立製藥（Relief）是一家專注於爲特定專科、未滿足和罕見病提供創新治療方案的生物製藥公司。今天，該公司公佈了截至2024年6月30日的半年財務報告，並提供了公司最新進展。
Relief provided updates on its key development programs and strategic initiatives, including RLF-TD011, a hypochlorous acid topical spray designed for the treatment of epidermolysis bullosa (EB), and RLF-OD032, a novel liquid formulation of sapropterin dihydrochloride for the management of phenylketonuria (PKU).
瑞立製藥宣佈了其主要開發項目和戰略計劃的最新進展，包括針對表皮潰瘍性鬆解症（EB）的RLF-TD011，以及針對苯丙酮尿症（PKU）的一種新型多巴酚丁二酸鹽液體制劑RLF-OD032。
The Company reported significant financial improvements in the first half of 2024, with revenue up 85% and operating expenses down 45%, driven by strategic realignment and cost-reduction initiatives. Investments in R&D, however, were stable. Remaining debt-free, the Company expects its cash reserves of CHF 15.1 million as of August 30, 2024, and projected revenue to fund operations into at least 2026.
該公司報告稱，2024年上半年財務狀況顯著改善，營業收入增長85%，營業費用下降45%，這得益於戰略調整和成本削減措施。然而，研發投資保持穩定。公司預計其1510萬元的現金儲備和預計收入能夠支撐至少到2026年。
The Relief 2024 half-year report is available on the Company's website.
瑞立製藥2024上半年報告已經發布，可在此處查閱。 公司的網站.
ABOUT RELIEF
Relief is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety, and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief's portfolio offers a balanced mix of marketed, revenue-generating products, proprietary, globally patented TEHCLO and Physiomimic platform technologies and a targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare skin diseases, rare metabolic disorders, and rare respiratory diseases. In addition, Relief is commercializing several legacy products via licensing and distribution partners. Headquartered in Geneva, Relief is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTY. For more information, visit .
關於救濟
Relief是一家商業化階段的生物製藥公司，致力於推進治療範式，提高治療效果，安全性和便利性，從而造福於患有特定專業和罕見疾病的患者。 Relief的組合產品提供了平衡的市場，產生收入，專有，全球專利TEHCLO和Physiomimic平台技術以及定向臨床開發管道，包括三個核心治療領域：罕見的皮膚病，罕見的代謝性疾病和罕見的呼吸道疾病。此外，Relief通過授權和分銷合作伙伴商業化了數種傳統產品。 總部設在日內瓦，Relief在SIX Swiss Exchange上市，代碼爲RLF，在OTCQb上引用代碼爲RLFTF和RLFTY。 有關更多信息，訪問。
CONTACT :
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
Chief Financial Officer
contact@relieftherapeutics.com
聯繫方式 :
RELIEF THERAPEUTICS Holding SA
Jeremy Meinen
致富金融(臨時代碼)
contact@relieftherapeutics.com
DISCLAIMER
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, including its ability to achieve its corporate, development and commercial goals, and other factors which could cause the actual results, financial condition, performance or achievements of Relief to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. A number of factors, including those described in Relief's filings with the SIX Swiss Exchange and the U.S. Securities and Exchange Commission (SEC), could adversely affect Relief. Copies of Relief's filings with the SEC are available on the SEC EDGAR database at www.sec.gov. Relief does not undertake any obligation to update the information contained herein, which speaks only as of this date.
免責聲明
本新聞稿包含前瞻性聲明。前瞻性聲明涉及已知和未知的風險、不確定性，包括實現其企業、開發和商業目標的能力，以及其他可能導致Relief的實際結果、財務狀況、業績或成就與任何未來結果、業績或成就存在實質性差異的因素。一些因素，包括在Relief向SIX瑞士交易所和美國證券交易委員會（SEC）提交的文件中描述的那些因素，可能對Relief產生不利影響。Relief的SEC備案文件可在SEC EDGAR數據庫的www.sec.gov上獲取。Relief不承擔任何更新此處所含信息的義務，該信息僅以本日期爲準。
SOURCE: Relief Therapeutics Holdings AG
SOURCE：Relief Therapeutics Holdings AG
譯文內容由第三人軟體翻譯。